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Abstract
Fluoroquinolones are increasingly used for the treatment of infections caused by multidrug-resistant Mycobacterium tuberculosis. Our
study was designed to determine the frequency of the emergence of ciproﬂoxacin-resistant isolates in a university hospital (Rabta Uni-
versity Hospital Tunis, Tunisia) and to characterize the mutations responsible for the resistance phenotype. A total of 495 clinical
M. tuberculosis isolates obtained from January 2005 to July 2008 were investigated for their susceptibility to ciproﬂoxacin, using the stan-
dard proportion method, PCR and DNA sequencing. Four resistant isolates (0.8%) were identiﬁed. Among these, only two carried point
mutations in gyrA leading to amino acid changes other than the phenotypically silent S95T substitution. No gyrB missense mutations
were found in any of the clinical isolates. Although ﬂuoroquinolone resistance is still rare in Tunisia, accurate surveillance is needed in
order to control the possible emergence of resistance to ﬂuoroquinolones, which are essential for the successful treatment of multi-
drug-resistant tuberculosis.
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Introduction
The increasing incidence of multidrug-resistant (MDR) tuber-
culosis (TB), which involves bacilli resistant to both isoniazid
and rifampin, the two main anti-TB drugs, is a worldwide
health problem [1]. Therefore, effective second-line drugs,
such as ﬂuoroquinolones, are needed for the treatment of
MDR TB [2]. These drugs, which are the ﬁrst new antimyco-
bacterial agents to become available since the discovery of
rifampin [3], showed good activities against Mycobacterium
tuberculosis, and could play a pivotal role in the second-line
drug regimens used in the treatment of MDR TB [4].
Quinolones inhibit the bacterial type II topoisomerase
DNA gyrase, an ATP-dependent enzyme essential for DNA
supercoiling, which is required for DNA replication and gene
transcription [5]. The enzyme consists of two proteins, GyrA
and GyrB, encoded, respectively, by gyrA and gyrB [5]. The
genetic basis of acquired ﬂuoroquinolone resistance is mainly
the alteration of DNA gyrase, especially by mutations occur-
ring in a short sequence termed the quinolone resistance-
determining region (QRDR) of the gyrA gene, and more
rarely in gyrB [6,7]. These mutations are frequently clustered
at codons 90 and 94 in gyrA, and at codons 495, 516 and
533 in gyrB [8–10].
Molecular characterization of resistance to ﬂuoroquinol-
ones in M. tuberculosis isolates from Tunisia has never been
performed. Hence, the ﬁrst objective of our study was to
determine the rate of ﬂuoroquinolone resistance in an urban
university hospital (Rabta Centre, Tunis, Tunisia) during a
2.5-year period (January 2005 to July 2008), and then to
identify the molecular mechanism involved in resistance.
Materials and Methods
Bacterial isolates
During January 2005 to July 2008, all M. tuberculosis isolates
obtained at Rabta University Hospital were investigated for
ciproﬂoxacin resistance.
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Culture of mycobacterial isolates was performed on
Lo¨wenstein–Jensen medium, and all M. tuberculosis isolates
were biochemically characterized and conﬁrmed by the
AccuProbe method (Gen-Probe Inc., San Diego, CA, USA).
Susceptibility testing for anti-TB drugs was performed on
Lo¨wenstein–Jensen medium according to the standard proce-
dure [11,12]. The critical concentrations of rifampin, isonia-
zid, ethambutol, streptomycin, ciproﬂoxacin, ethionamide
and pyrazinamide were 40, 0.2, 1, 10, 10, 100 and 20 mg/L,
respectively. Resistance to ciproﬂoxacin was deﬁned as
>10% growth on ciproﬂoxacin-containing medium as com-
pared to control medium.
MICs
The MICs of ciproﬂoxacin (0.25–8 mg/L) were determined
for all resistant isolates, using the conventional indirect pro-
portion method with the agar dilution technique. Resistance
was deﬁned as an MIC of >2 mg/L [13].
DNA extraction
Template DNA was prepared by heat killing of mycobacteria
at 95C for 30 min, followed by sonication at room temper-
ature for 25 min and centrifugation at 14 000 g for 5 min.
The supernatant was kept at )20C until being used.
Generation of PCR-ampliﬁed DNA
For gyrA, a DNA fragment of 216 bp, corresponding to the
QRDR, was generated by PCR with the primer pair Pri9 (5¢-
CGCCGGGTGCTCTATGCAATG-3¢) and Pri8 (5¢-CGGT
GGGTCATTGCCTGGCGA-3¢), used at 4 lM. Ampliﬁcation
reactions were performed as previously described by Guil-
lemein et al. [7]. For gyrB, a 322-bp fragment was ampliﬁed
using the primer pair gyrBA (5¢-GAGTTGGTGCGCGCTAA-
GAGC-3¢) and gyrBE (5¢-CGGCCATCAGCACGATCTTG-
3¢) at 0.4 lM. Ampliﬁcation reactions were performed as
previously described by Dauendorffer et al. [14].
Ampliﬁed products were subjected to electrophoresis in
2% agarose gels in Tris–borate–EDTA buffer and visualized
under UV light. These products were then used as templates
in direct nucleotide sequencing.
DNA sequencing
DNA sequencing of both strands was performed with an
ABI PRISM Dye terminator cycle sequencing ready reaction
kit (Applied Biosystems, Paris, France) and the reactions
were analysed on an ABI Prism 310. The Blast 2 Sequences
computer program was used for DNA sequence compari-
sons (http://www.ncbi.nlm.nih.gov).
Results
Among the 495 isolates collected at Rabta hospital during
the study period, four (0.8%) exhibited ciproﬂoxacin resis-
tance and 491 were characterized as fully susceptible to cip-
roﬂoxacin. Drug susceptibility evaluation of these four clinical
isolates showed a multiresistance proﬁle in one case, isolated
resistance to ciproﬂoxacin in one case, and resistance to cip-
roﬂoxacin and ethionamide or streptomycin in the two
remaining cases (Table 1). The MICs of ciproﬂoxacin for the
resistant isolates ranged between 2 and 4 mg/L (Table 1).
Complete medical records were available for all four
patients. They revealed a new case of pulmonary TB in two
patients, one new extrapulmonary form of TB diagnosed
from a colic biopsy in one patient, and one case of previ-
ously treated pulmonary TB with an anti-TB history including
rifampin, isoniazid, pyrazinamide and streptomycin given dur-
ing 3-month to 6-month periods [15].
Moreover, medical records revealed a negative human
immunodeﬁciency virus status in all cases.
The sequencing data showed that all investigated isolates
possessed at least one gyrA mutation in the QRDR, all but one
TABLE 1. Resistance patterns of
ciproﬂoxacin-resistant Mycobacte-
rium tuberculosis isolates deter-
mined with the proportion method
and DNA sequencing
Patient Isolate
Isolation date
(day/month/year)
Drug resistance shown
by proportion method
CIP MIC
(mg/L)
Sequencing
resultsa
GyrA GyrB
1 2107 05/03/2005 CIP–ETH 4 S95T NM
I92M
2 8832 14/07/2005 CIP 2 S95T NM
3 9742 23/11/2005 INH–RMP–CIP–SM 4 S95T R516R
V530V
L531L
4 7459 03/03/06 CIP–SM–ETH 4 S95T NM
A90L
G88G
CIP, ciproﬂoxacin; ETH, ethionamide; INH, isoniazid; NM, no mutation; RMP, rifampin; SM, streptomycin.
aDeduced amino acid changes; the numbering system is based on the M. tuberculosis GyrA and GyrB sequences [30].
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leading to an amino acid change, whereas the gyrB alterations,
observed in only one strain, were are all silent (Table 1).
However, the S95T GyrA mutation detected in all strains
is considered to be a phenotypically silent alteration not
associated with resistance to ﬂuoroquinolones [16].
Accordingly, in two cases (isolates 8832 and 9742), resis-
tance to ciproﬂoxacin occurred without a causative mutation
in the QRDR of gyrA (Table 1).
Discussion
Acquired resistance to ﬂuoroquinolones in M. tuberculosis has
been predominantly attributed to gyrA mutations, which are
frequently clustered in codons 90 and 94, whereas gyrB alter-
ations are rarely observed in clinical isolates [17,18].
In our study, no gyrB missense mutations were observed
in the clinical M. tuberculosis ciproﬂoxacin-resistant investi-
gated isolates. However, it is interesting to note that no gyrA
mutations in codon 94 were observed, and only one isolate
carried an A90L substitution, which has not been previously
reported.
The compilation of data available from many studies indi-
cated that other gyrA mutations located in variable positions,
such as D89V or A74S could be associated with a resistance
phenotype [19,20].
In our study, a novel mutation located in codon 92 and
leading to an amino acid change from isoleucine to methio-
nine was observed in one strain. Moreover, the mutation
reported in a clinical isolate that involved codon 88 (G88C)
was not found in our isolates [21], and the alteration
observed at this position (G88G) was silent (isolate 7459;
Table 1).
We observed that all isolates tested carried an S95T sub-
stitution in gyrA. This is consistent with the previously
reported ﬁnding that this substitution is a marker of the evo-
lutionary history of the organism and does not correlate
with drug resistance [16].
Evaluation of MICs showed a high ciproﬂoxacin resistance
level (MIC 4 mg/L) in the MDR isolate and in the two isolates
with novel gyrA mutations. However, a low resistance level
was observed in strain 8832 which carried only the
substitution S95T and showed an isolated resistance to cipro-
ﬂoxacin. An association between MDR and high-level cipro-
ﬂoxacin resistance was reported earlier in M. tuberculosis
clinical isolates with no gyrA mutations observed in the
QRDR hot spot region (from codons 90 to 94) [22]. Accord-
ing to our preliminary results, it seems that the novel gyrA
mutations were associated with acquisition of high-level cip-
roﬂoxacin resistance. Even if these mutations do not occur in
drug-sensitive strains, further investigation is still required to
conﬁrm the role of these gyrA alterations in the development
of ciproﬂoxacin resistance in M. tuberculosis clinical isolates,
as the same level (MIC 4 mg/L) has been observed in one iso-
late (9742) that carried only the phenotypically silent S95T
gyrA mutation; therefore, this ﬁnding does not exclude the
presence of additional resistance mechanisms.
The new mutations identiﬁed in our study will provide
additional information for analysis of the effect of quinolones
on M. tuberculosis, and they may also serve as epidemiological
markers.
Among the four ciproﬂoxacin-resistant isolates investigated,
two possessed gyrA mutations other than S95T substitution. A
similar rate was observed in M. tuberculosis strains isolated in
Taiwan and China [7,22]. Mutations in gyrA mutations were
identiﬁed in up to 89.5% of Italian isolates [23], but they were
detected in only 10.3% of Indian clinical isolates [24].
For the two ciproﬂoxacin-resistant isolates without gyrA
or gyrB mutations that correlate with drug resistance, it
appears that they have acquired resistance through muta-
tions elsewhere in the target genes or by other mechanisms,
e.g. decreased cell wall permeability or active drug efﬂux
[25,26]. Further investigations are needed. Studies performed
earlier in Tunisia on M. tuberculosis, including MDR isolates,
revealed no case of ﬂuoroquinolone resistance [27,28].
According to a report from a worldwide network of
supranational reference laboratories representing approxi-
mately 80 countries, the rate of ﬂuoroquinolone resistance
varied between 4.4% and 5.3% [29]. This resistance was, in
fact, frequently observed in MDR strains (c. 19.3%) [29].
According to our study, the prevalence of ﬂuoroquinolone
resistance observed in the Rabta hospital during January
2005 to July 2008 was estimated to be 0.8%. No relationship
was noted between the mutations and the phenotypic resis-
tance proﬁles of clinical M. tuberculosis isolates.
Although ﬂuoroquinolone resistance is still rare in Tunisia,
accurate surveillance in order to control the possible emer-
gence of resistant strains is essential, particularly with
respect to the treatment of MDR TB.
Nucleotide sequence accession numbers
The sequences with novel mutations found in this study have
been deposited in GenBank under accession numbers
FJ743481 and FJ743482.
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